Showing results (91-100 of 149) with videos related to
Sort By:
Pageof 15
Breast Cancer Research : BCR|February 20, 2020
TBCRC 002: a phase II, randomized, open-label trial of preoperative letrozole with or without bevacizumab in postmenopausal women with newly diagnosed stage 2/3 hormone receptor-positive and HER2-negative breast cancerChristos Vaklavas, Brian S Roberts, Katherine E Varley, et al.Journal for Immunotherapy of Cancer|August 14, 2021
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of breast cancerLeisha A Emens, Sylvia Adams, Ashley Cimino-Mathews, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 19, 2022
Evaluation of a Liquid Biopsy-Breast Cancer Methylation (LBx-BCM) Cartridge Assay for Predicting Early Disease Progression and Survival: TBCRC 005 Prospective TrialKala Visvanathan, Leslie Cope, Mary Jo Fackler, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 22, 2016
Monitoring of Serum DNA Methylation as an Early Independent Marker of Response and Survival in Metastatic Breast Cancer: TBCRC 005 Prospective Biomarker StudyKala Visvanathan, MaryJo S Fackler, Zhe Zhang, et al.JCO Precision Oncology|April 26, 2023
Association Between Biomarkers and Clinical Outcomes of Pembrolizumab Monotherapy in Patients With Metastatic Triple-Negative Breast Cancer: KEYNOTE-086 Exploratory AnalysisSherene Loi, Roberto Salgado, Peter Schmid, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 15, 2015
Phase II Study of Lapatinib in Combination With Trastuzumab in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer: Clinical Outcomes and Predictive Value of Early [18F]Fluorodeoxyglucose Positron Emission Tomography Imaging (TBCRC 003)Nancy U Lin, Hao Guo, Jeffrey T Yap, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 12, 2019
TBCRC 032 IB/II Multicenter Study: Molecular Insights to AR Antagonist and PI3K Inhibitor Efficacy in Patients with AR+ Metastatic Triple-Negative Breast CancerBrian D Lehmann, Vandana G Abramson, Melinda E Sanders, et al.Plos Medicine|December 30, 2006
A genome-wide screen for promoter methylation in lung cancer identifies novel methylation markers for multiple malignanciesDavid S Shames, Luc Girard, Boning Gao, et al.Science Translational Medicine|April 22, 2026
Peripheral blood transcriptional profiling predicts tumor subtype and neoadjuvant chemoimmunotherapy outcomes in human breast cancerXiaopeng Sun, Andres A Ocampo, Ann Hanna, et al.NPJ Breast Cancer|October 12, 2019
Two may be better than one: PD-1/PD-L1 blockade combination approaches in metastatic breast cancerDavid B Page, Harry Bear, Sangeetha Prabhakaran, et al.Pageof 15